Current Affairs – August, 2019

Latest Current Affairs August, 2019 with Current Affairs, news summary on current events of National and International importance of August, 2019 for Banking, SSC, CLAT, UPSC, State PCS, IBPS, Railways and other Competitive Examinations.

PDF Compilation of these updates can be downloaded from This Link

India suspends Thar Link Express

India suspended weekly Jodhpur-Munabao Thar Link Express amid the ongoing tension with Pakistan over the Kashmir issue. This move comes days after India cancelled Samjhauta Express from its side after Pakistan had announced suspension of all train services to India.

About Thar Express

It is Indian portion of international passenger train operated weekly (every Saturday morning) by Indian Railway using its own coaches and locomotives, between Jodhpur and Munabao in India. Passengers from Munabao (Rajastan) after clearing customs are transported to across border to Zero Point station where Thar Express takes passengers to Karachi, Pakistan via Munabao (India)-Khokhrapar (Pakistan’s Sindh province) border crossing. It carries only passengers and not goods.

Background: The agreement to link two countries by rail service through Munabao-Khokhrapar link was signed in 2006 with aim to facilitate people-to-people contact. It was revived after gap 41 years after Munabao-Khokhrapar rail link was destroyed during 1965 war between two countries. This agreement was extended in 2018 for three years till January 31, 2021. According to estimates, over 4 lakh passengers from both countries have taken train in the past 13 years.

About Samjhauta Express

It is another passenger train running between India and Pakistan. It runs from Delhi to Attari on Indian side and from Lahore to Wagah on the Pakistan side. Its service was started in 1976 following Shimla Agreement.

Month:  Categories: International

Tags:

PRETOMANID: US FDA approves new drug for drug-resistant TB

United States (US) Food and Drug Administration (FDA) has approved new drug-Pretomanid for treating drug-resistant strain of Tuberculosis (TB). Pretomanid is novel compound developed by New York-based non-profit organisation TB Alliance. It is used alongside two other antibiotics (bedaquiline and linezolid) to treat extremely drug-resistant strain of tuberculosis. This three-drug regimen is collectively known as BPaL regimen and it can cure highly drug-resistant strains of tuberculosis by drastically shortening treatment period.

Significance of BPaL regimen

Before FDA approval to this combination therapy, the most common treatment used for extremely drug resistace tuberculosis required patients to take around 30 pills day plus sometimes daily injections for at least 18 months. This new treatment lowers that dose to 5 pills/day over 6 months for most patients. This treatment regimen had achieved 90% success rate during six months of treatment and six months of post-treatment follow-ups after it was tested on 109 patients at three sites in South Africa.

Month:  Categories: Science & Technology

Tags:

Advertisement